Known artists

PC to TV: Apple Hopes to Bridge the Gap

During the past few years you have probably heard terms like “Movies on Demand” or “Video on Demand”. The number of movie titles are still very limited and all the hype surrounding “Video on Demand” has turned out to be a real disappointment. Cable companies just don’t have much to offer when it comes to offering a wide selection of “Video on Demand”. Apple Computer (Nasdaq: AAPL) is about to enter this market full steam in a unique way. Microsoft (Nasdaq: MSFT) still has a learning curve when it comes to audio and video delivery and is just entering the market where Apple was 5 years ago. It has recently introduced Zune, an iPod скачать Хранители competitor.

The Online Video Content Market
The internet, on the other hand, has made great strides in the “Video on Demand” market in just the past 3 years. The number of websites showing video clips that include news, corporate interviews, movie trailers, old and new TV shows, product advertisements and short films has grown exponentially. The content does vary widely and currently is spread across a large number of niche markets. These niche markets are served by a large number of individual websites. The number of people who visit these websites is huge.

An Opportunity Exists –
Bridging the Gap
There exists a tremendous opportunity for bridging the gap between online video content and the TV screen. If you can find old episodes of your favorite TV show or an old sporting event, you are likely going to want to watch it on a Антикризисная программа! Экскаваторы Hyundai на 10% дешевле. large TV screen. The question Sony Ericsson K630i is how to bridge the PC to TV gap.

Current Bridging the Gap Solutions
танцевальный коврик usb This PC to TV convergence has been slowly evolving over the past few years. A quick trip to Best Buy and a conversation with one of their helpful employees reveals there are a few ways to “bridge the gap”. For instance, you can purchase the necessary cable to connect your computer’s VGA output to your TV’s VGA input. There are plenty of websites with directions for the steps you need to follow. Another option is using a PC to TV converter. There are several on the market such as the Manhattan PC to TV Converter, while there are also wireless converters and converters for HDTV.

Get Ready for the Apple Solution
On September 12, 2006 Apple issued a press release and announced its плазменные панели панасоник much anticipated new product launch which it referred to as “iTV”. According to Apple’s website, however, iTV is the project’s internal code name and will not be the final product name. “Here we go again! First music, then TV shows, and now movies,” said Steve Jobs, Apple’s CEO. “In less than one year we’ve grown from offering just five TV shows to offering over 220 TV shows, and we hope to do the same with movies. iTunes is selling over one million videos a week, and we hope to match this with movies in less than a year.”

The iTV is a network media box that streams of your iTunes-based media–including music, movies, TV shows, podcasts, and photos directly from your PC or Mac to your TV, HDTV or home entertainment system. This will allow people to enjoy the video content they select on their TV screen while relaxing on their водонагреватель электролюкс couch or easy-boy-chair, rather than sitting at their desk staring at Brother Star 55 their small computer screen.

Conclusion
If Apple can successfully distribute its iTV product to the masses and if that product proves стиральные машины аег to be an easy-to-use way to link dormeo orthopedic the PC to the TV, they will be setting a standard just like they did with their and iPod. As Apple’s track record has proven, first one to the market with a great concept and easy-to-use hardware/software proves to be highly successful.

Data Exclusivity: The Indian Position

Introduction:

Data exclusivity refers to a practice whereby, for a fixed period of time, test and other data provided to the drug regulatory authority (“DRA”) of a country (to demonstrate the efficacy and safety of a medicinal product [1]) in order to obtain an authorization to place the product on the market in that country, are not allowed to be used to register a therapeutically equivalent generic version of that product. Oftentimes, this data arises out of many years of research and clinical trials and is very expensive for the originator of the drug to produce. The framework for pharmaceutical regulation and authorization attempts to protect the investment of companies in their innovations by providing periods of so-called data exclusivity.

In essence, data exclusivity refers to a period during which no third party applicant can rely on data filed by the original applicant for a marketing authorization. Accordingly, during this exclusivity period any subsequent applicant would need to have generated its own data to support the safety and efficacy of the product. It has, therefore, been argued, that data exclusivity is a misleading term; a more appropriate term would be market exclusivity.

The most important international TOYOTA CUP 21 agreement dealing with the use of data submitted for regulatory approval is the World Trade Organization (“WTO”)’s Agreement on TRIPS. Article 39.3 of TRIPS (reproduced below) obliges countries to protect against unfair commercial use of confidential data on new chemical entities submitted by companies to obtain approval for marketing new drugs from a regulatory agency. However, not all WTO member states have enacted data exclusivity laws as described. This is because Article 39.3 allows considerable discretion as to what member states must do. Nowhere does Article 39.3 state that countries should provide exclusive ноутбук тошиба rights to the originator of the data for a given period or a minimum term of protection.

More importantly, it is not clear whether the phrase “unfair commercial use” includes use of the originator’s data by the regulatory agency to assess applications by generic competitors. This has been argued not to amount to “unfair commercial use” so long as the regulatory agency does not disclose the data to the generic competitor. In terms of this interpretation, Article 39.3 does not require data exclusivity.

On the other hand, according to the research-based pharmaceutical industry, the only way to effectively protect test data against unfair commercial use is to provide an exclusivity period for the use of the data.

Both the Office of the United States Trade Representative and the European Union (”EU”) have urged that Article 39.3 of the TRIPS Agreement established an exclusivity obligation. According to the EU, all that is left to member countries is the determination of the duration thereof.

In addition to Article 39.3, there have been other bilateral arrangements and regional free trade agreements signed or under negotiation by the US in the wake of the failure of multilateral negotiations in the WTO, which contain data exclusivity provisions. The most significant of the trade negotiations wrapped up by the USTR is Central American Free Trade Agreement (”CAFTA”).

The Indian Position

In 2003, the Government of India issued a statement that –

“the Government does not have a position on data exclusivity at the moment. But it is clear that we have no скачать Жилец obligation under TRIPS (trade- related aspects of intellectual property rights) to have provisions for the same in the country.”

The Government of India was of the opinion that Article 39.3 only requires WTO members to protect the test data against any “unfair commercial use” or “unfair competition”. It neither includes market exclusivity to the innovator nor does it create market protection. The rationale/basis for such a view has originated from the term “unfair competition” as described by the World Intellectual Property Organization (“WIPO”), that “the repression of unfair competition is not concerned with exclusive rights, but is directed against acts of competition contrary to honest practices in industrial or commercial matters, for example in relation to undisclosed information (trade secrets).”

Since the repression of “unfair competition” does not advocate any kind of exclusive rights nor the word “exclusivity” has been mentioned anywhere in the Article, the demand to give market exclusivity to pharmaceutical companies or the innovator on the basis of Article 39.3 would be unfair.

Also, a Government official reportedly stated that –

“TRIPS only requires us to protect test data against unfair use under Article 39.3, but there is nothing that says that we have to provide marketing exclusivity. Interpretations vary depending on which side you are on. It is only when a case comes up at the Appellate Authority at WTO can there be clarity……Under the

This entry was posted on Friday, February 13th, 2009 at 5:54 pm and is filed under collaboration, marketing. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.